Trevi Therapeutics

TRVI

Market cap $1.7B

Trevi Therapeutics, Inc. ( TRVI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Ryan Deschner - Raymond James & Associates, Inc., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Judah Frommer - Morgan Stanley, Research Division Serge Belanger - Needham & Company, LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division William Wood - B. Riley Securities, Inc., Research Division Kaveri Pohlman - Clear Street LLC Presentation Operator Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2025 Earnings Conference Call.

Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. EST NEW HAVEN, Conn.

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.

Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET NEW HAVEN, Conn.

Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) Associate Professor Imran Satia will give a poster presentation on the patient-reported outcomes from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with refractory chronic cough (RCC) NEW HAVEN, Conn. , Oct. 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the acceptance of two abstracts for presentation at the CHEST 2025 Annual Meeting, to be held from October 19 to 22 in Chicago, Illinois.

NEW HAVEN, Conn. , Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that data from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC, will be highlighted in two poster presentations at the European Respiratory Society (ERS) Congress 2025.

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director Farrell Simon - Chief Commercial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Welcome to this session of the Morgan Stanley Global Healthcare Conference. I'm excited to welcome the team from Trevi.

NEW HAVEN, Conn. , Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in September.

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants g - Corporate Participant e - Corporate Participant Farrell Simon - Chief Commercial Officer James V. Cassella - Chief Development Officer Jennifer L.

Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET    NEW HAVEN, Conn.